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Abstract 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an
environmental toxin that activates the aryl hydrocarbon receptor
(AhR) and disrupts multiple endocrine signaling pathways. T47D
human breast cancer cells express a functional estrogen receptor
K (ERK) and AhR, and treatment of these cells with 17L-
estradiol (E2) or TCDD resulted in a rapid proteasome-
dependent decrease in immunoreactive ERK and AhR proteins
(s 60^80%), respectively. E2 did not affect the AhR, whereas
TCDD induced proteasome-dependent degradation of both the
AhR and ERK in T47D and MCF-7 human breast cancer cells,
and these responses were specifically blocked by proteasome
inhibitors. Thus, TCDD-induced degradation of ERK may
contribute to the antiestrogenic activity of AhR agonists and
this pathway may be involved in AhR-mediated disruption of
other endocrine responses. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
Key words: Proteasome; Estrogen receptor K ;
Aryl hydrocarbon receptor; Degradation; Crosstalk;
Breast cancer cell
1. Introduction
The estrogen receptor (ER) is a ligand-activated transcrip-
tion factor that is a member of the nuclear receptor super-
family [1,2], and two ER subtypes (ERK and ERL) and multi-
ple variants have been characterized [3^6]. Estrogens play an
important physiological role in male and female reproduction
and development and have also been characterized as risk
factors for breast and endometrial cancer in women [7].
Drugs used for endocrine therapy of early-stage breast can-
cer include ER antagonists, such as tamoxifen, that inhibit ER
action in ER-positive mammary tumors and breast cancer
cells in culture [8]. We have been investigating aryl hydrocar-
bon receptor (AhR)-mediated inhibition of estrogen-induced
responses in the rodent uterus and mammary gland and in
breast cancer cell lines [9,10]. The ligand-activated AhR com-
plex inhibits estrogen-induced gene expression and their de-
rived proteins or dependent activities and also inhibits growth
of estrogen-dependent mammary tumors in rodent models.
Most studies with the AhR have used the environmental tox-
icant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) as a proto-
typical ligand; we have also identi¢ed selective AhR modula-
tors such as 6-methyl-1,3,8-trichlorodibenzofuran (MCDF)
that are relatively non-toxic but are e¡ective inhibitors of
rodent mammary tumor growth [11]. At least one mechanism
of inhibitory AhR^ERK crosstalk involves direct interaction
of the AhR complex with inhibitory dioxin response elements
(iDREs) identi¢ed in the 5P-promoter regions of E2-responsive
cathepsin D, pS2 and c-fos genes [12^14]. However, results of
ongoing studies indicate that AhR agonists also inhibit E2-
induced expression of several genes that do not have func-
tional iDREs.
Previous studies in the rodent uterus and breast cancer cells
have shown that TCDD downregulates ERK [15^20], and this
response may contribute to inhibitory AhR^ERK crosstalk.
Recent reports indicate that both 17L-estradiol (E2) and
TCDD induce proteasome-dependent degradation of ERK
and the AhR respectively [21^25], and previous studies have
shown that TCDD downregulates the AhR in vitro and in
vivo [26^29]. This study probes the role of proteasome acti-
vation in mediating inhibitory AhR^ERK interactions in
ERK-positive MCF-7 and T47D breast cancer cell lines that
also express a functional AhR [19].
2. Materials and methods
2.1. Cells, chemicals and biochemicals
T47D and MCF-7 human breast cancer cells were obtained from
American Type Culture Collection (Rockville, MD). TCDD and
MCDF were prepared in this laboratory, and shown to be s 99%
pure by gas chromatographic analysis. E2, benzo[a]pyrene (BaP),
chloroquine, calpain inhibitor II, EST, MG132 and PSI were the
highest quality available from commercial sources. Antibodies for
ERK (sc-544), AhR (sc-8088), Sp1 and Arnt (sc-8076) proteins were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
The human ERK, AhR and AhR nuclear translocator (Arnt) full
length cDNA probes were cloned into the pcDNA3.1 expression vec-
tor (Invitrogen) and used to translate in vitro standards for Western
blots using a reticulocyte lysate method.
2.2. Cell maintenance and protein isolation
Cells were grown on monolayer cultures in Sigma MEM K mod-
i¢cation (T47D) or DMEM Ham F12 (MCF-7) media with phenol
red supplemented with 2.2 g/l sodium bicarbonate, 0.2 g/l bovine
serum albumin (bovine, fraction V), 0.01 g/l apo-transferrin (human),
5% fetal bovine serum (Intergen, Purchase, NY), and antibiotic^anti-
mycotic solution, pH 7.4. Cells for experiments were seeded into
35 mm 6 well tissue culture plates in phenol-free media (DMEM
Ham F-12, Sigma) containing 2.5% charcoal-stripped fetal bovine
serum. The following day, the cells were treated and harvested at
designated time points as follows. Cells were washed once in ice
cold phosphate-bu¡ered saline and collected by scraping in 0.25 ml
ice cold lysis bu¡er (50 mM HEPES, pH 7.5, 150 mM NaCl, 10%
(v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 10 Wg/
ml aprotinin, 50 mM phenylmethylsulfonyl £uoride, 50 mM sodium
orthovanadate. The lysates were incubated on ice for 1 h with inter-
mittent vortexing followed by centrifugation (15 000Ug, 5 min, 4‡C).
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 8 3 0 - 5
*Corresponding author. Fax: (1)-409-862 4929.
E-mail: ssafe@cvm.tamu.edu
FEBS 23949 21-7-00
FEBS 23949 FEBS Letters 478 (2000) 109^112
Equal amounts of protein from each treatment group were separated
by SDS^PAGE and electrophoresed to PVDF membrane using a Bio-
Rad Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, Hercules,
CA); transfer bu¡er: 48 mM Tris, 39 mM glycine, 0.025% sodium
dodecyl sulfate (SDS). Membranes were blocked for 30 min in Blotto
(5% milk+TBS (10 mM Tris^HCl, pH 8.0, 150 mM NaCl), 0.05%
Tween-20), probed with the polyclonal antibodies for ERK (1:1000
dilution in Blotto), AhR (1:200), or Arnt (1:200) (see Section 2.1) for
5 h, washed 2U5 min in TBS+0.05% Tween 20, and probed with
secondary peroxidase-conjugated antibody (1:5000 in Blotto) for 2 h.
The membranes were then washed 3U5 min in TBS+0.05% Tween-20,
1U5 min in TBS, and visualized using the ECL detection system
(New England Nuclear, Boston, MA). Quantitation of Western blots
was performed using a Sharp JX-330 scanner (Sharp Corp., Mahwah,
NJ) and Zero-D Scanalytics software (Scanalytics Corp., Billerica,
MA).
2.3. Statistical analysis
Relative ERK and AhR levels are plotted as a percentage of total
densometric units observed for dimethylsulfoxide (DMSO; control)-
treated cells for individual PVDF membranes. Results are presented
as means þ S.E.M. for at least three separate determinations for each
treatment group. All experiments were performed at least two times.
Statistical di¡erences between groups were determined by analysis of
variance followed by Fisher’s protected LSD test for signi¢cance
(P6 0.05).
3. Results and discussion
The results demonstrate that after treatment of T47D and
MCF-7 cells (Fig. 1a,b) with E2, TCDD or their combination,
there is a rapid decrease in immunoreactive ERK protein that
persists for up to 24 h. The proteasome inhibitors MG132 and
PSI block both E2- (Fig. 1c) and TCDD- (Fig. 1d) mediated
degradation of ERK, whereas protease inhibitors had no ef-
fect. TCDD also induces degradation of the AhR in T47D
cells (Fig. 2a), and this response is blocked by proteasome
inhibitors (MG132 and PS1) but not protease inhibitors
(Fig. 2b). In contrast, E2 does not a¡ect levels of AhR protein
(Fig. 2a) demonstrating that proteasome-dependent inhibitory
Fig. 1. Modulation of ERK protein levels through the ER and AhR pathways. T47D (a) and MCF-7 (b) cells treated with 10 nm E2, 10 nM
TCDD, or 10 nM E2 plus 10 nM TCDD display a time-dependent decrease in immunoreactive ERK protein levels. 50 Wg aliquots of whole
cell lysates were separated by SDS^PAGE (7.5% acrylamide) and immunoblotted for ERK (see Section 2). Cotreatment with E2 plus TCDD
signi¢cantly decreased ERK levels relative to E2 treatment alone by 40^80% after 3 h (a, b), 6 h (b) and 24 h (b). Pretreatment of T47D cells
for 1 h with the proteasome inhibitors MG132 and PSI (10 WM) followed by a 3 h treatment of 10 nM E2 (c) or 10 nM TCDD (d) blocked
degradation of ERK protein. The protease inhibitors calpeptin (CALPEP), chloroquine (CHLOR), calpain inhibitor II (CAL2), and EST
(10 WM) had no e¡ect. C = DMSO, E = E2, T = TCDD. n = 3, mean þ S.E.M. *P6 0.05. Levels of immunoreactive Sp1 protein for each treat-
ment group (c and d) and for the E2+TCDD treatment groups (a and b) are shown as a loading control. We have previously shown that levels
of this protein are una¡ected by E2, TCDD or their combination (data not shown). The proteasome-dependent e¡ects of TCDD, E2 and their
combination on immunoreactive ERK in whole cell extracts were also observed in nuclear extracts as determined in gel mobility shift assays
(data not shown).
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crosstalk between the two signaling pathways is unidirection-
al, namely AhRCERK. Selective and timely proteasome-de-
pendent degradation of proteins occurs at critical points dur-
ing di¡erentiation, cell cycle progression, oncogenesis, and
other highly regulated cellular processes [30,31]. It has been
suggested that E2-activated degradation of ER by protea-
somes may be an important pathway for limiting the duration
of estrogenic responses in target tissues [21], and our results
(Fig. 1) demonstrate that this pathway is also induced through
ligand (TCDD) activation of the AhR. The interactive pro-
teasome-dependent e¡ects of TCDD plus E2 are consistent
with reported inhibition of E2-induced gene expression, in
vitro cell proliferation and mammary tumor growth associ-
ated with AhR^ERK crosstalk [9^14].
Fig. 2. E2 does not induce a reciprocal degradation of AhR protein.
a: T47D cells were treated with 10 nM TCDD or 10 nM E2 for the
indicated lengths of time. 50 Wg aliquots of whole cell lysates were
separated on SDS^PAGE (7.5% acrylamide) and immunoblotted for
AhR (see Section 2). E2 did not signi¢cantly downregulate AhR
protein levels. b: Degradation of AhR protein after treatment with
10 nM TCDD for 3 h was signi¢cantly inhibited (relative to
TCDD/DMSO alone) by pretreatment (for 1 h) with proteasome in-
hibitors MG132 and PSI (10 WM). The protease inhibitors calpeptin
(CALPEP), chloroquine (CHLOR), calpain inhibitor II (CAL2) and
EST (10 WM) had no e¡ect. C = DMSO, E = E2, T = TCDD. n = 3,
mean þ S.E.M. *P6 0.05.
6
Fig. 3. Role of the AhR in ERK protein degradation. a: Treatment of MCF-7 cells with AhR agonists downregulates ERK protein levels. Cells
were treated with increasing concentrations of TCDD, BaP or MCDF for 3 h, and ERK protein levels were analyzed as described in Section 2.
b: Pretreatment (1 h) with the proteasome inhibitor MG132 (10 WM) followed by a 3 h treatment with 10 nM TCDD blocked ERK degrada-
tion in MCF-7 cells, whereas the protease inhibitor CALPEP had no e¡ect. The BaP-resistant MCF-7 cell line (MCF-7 BaPr) is AhR-non-re-
sponsive; treatment 10 nm TCDD for 3 h did not signi¢cantly alter ERK protein levels. Treatment with TCDD for longer periods did not af-
fect ERK levels, and analysis of nuclear extracts from these cells showed increased ER DNA binding in a gel mobility shift assay [32]. c: Whole
cell extracts from wild-type and BaPr MCF-7 cells were immunoblotted for relative AhR and Arnt protein levels. MCF-7 BaPr cells express
minimal levels of immunoreactive AhR protein relative to MCF-7 wild-type cells.
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The AhR interacts with structurally diverse ligands and
rank order structure^binding relationships correlate with
structure^activity relationships [9]. The results in Fig. 3a com-
pare the e¡ects of three AhR agonists, namely TCDD, BaP,
and MCDF, on ERK protein levels in MCF-7 cells. Their
order of potency for induction of proteasome-dependent deg-
radation of ERK protein (TCDDsBaPvMCDF) is similar to
their rank order for AhR binding and other AhR-mediated
responses suggesting that ERK degradation is mediated by the
AhR [9]. Moreover, the e¡ects of TCDD on ERK degradation
in wild-type MCF-7 cells are blocked by the proteasome in-
hibitor MG132 (Fig. 3b), whereas the protease inhibitor cal-
peptin did not a¡ect TCDD action. In contrast, TCDD did
not a¡ect ERK protein in E2-responsive, BaP-resistant MCF-
7 cells (Fig. 3b) that express minimal to non-detectable levels
of the AhR and higher levels of Arnt protein (Fig. 3c) [32,33]
con¢rming that the AhR is required for ligand-activated deg-
radation of ERK in breast cancer cells. These data suggest
that Ah non-responsiveness of BaP-resistant cells is associated
with limiting amounts of AhR expression.
The overall mechanisms for proteasome-dependent degra-
dation of ERK and the AhR have not been delineated and
results from di¡erent reports are variable [21^25]. For exam-
ple, one study showed that nuclear export was important for
cytosolic degradation of the AhR [24], whereas another report
suggested that nuclear localization was required for rapid
AhR degradation [25].
Thus, TCDD not only activates proteasome-dependent
downregulation of its own receptor, but also induces degra-
dation of ERK protein via proteasome-dependent pathways.
This unique AhR-activated/proteasome-dependent degrada-
tion of two receptor proteins in breast cancer cells is highly
selective since TCDD does not a¡ect levels of several other
regulatory proteins in these cells including cyclins A, E, D and
H, cdk-2, cdk-4, cdk-7, p27, p21, cdc25A [34] and Sp1 protein
(data not shown). These results demonstrate a novel mecha-
nism of inhibitory AhR^ERK crosstalk in ERK-positive breast
cancer cell lines. Moreover, it is possible that other cell-spe-
ci¢c endocrine-disrupting activities of TCDD [9,10] that in-
clude downregulation of receptors for hormones and other
mitogens may also be associated with selective proteasome-
dependent protein degradation pathways, and these are cur-
rently being investigated.
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